+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Human Microbiome Market Analysis 2021-2031

  • PDF Icon

    Report

  • 224 Pages
  • May 2022
  • Region: Global
  • Research Nester Pvt. Ltd
  • ID: 5624592
Description Jump to:
The global human microbiome market is anticipated to grow with a CAGR of 22.3% over the forecast period, i.e., 2022 - 2031. Factors such as the growing focus on microbiome therapeutics, followed by the surge in prevalence of lifestyle-related diseases, and the increasing research and developments on human microbiome are projected to add to the growth of the market in the coming years. The market is estimated to garner a revenue of near to USD 3250 Million by the end of 2031, up from a revenue of close to USD 440 Million in the year 2021.

The global human microbiome market is segmented by numerous segments which include segmentation by product, disease type, organism type, application, technology, and by region. By product, the market is segmented into probiotics, prebiotics, diagnostic tests, drugs, and others. By the end of 2031, the probiotics segment is anticipated to garner the largest revenue of about USD 1430 Million by the end of 2031. Additionally, in the year 2021, the segment generated a revenue of around USD 190 Million.

On the basis of regional analysis, the global human microbiome market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in North America, out of the market in all the other regions, is anticipated to garner the largest revenue of near to USD 1860 Million by the end of 2031. Additionally, in the year 2021, the market in the region generated a revenue of more than USD 250 Million.

However, the stringent government regulations is expected to operate as key restraint to the growth of global human microbiome market over the forecast period.

Some of the prominent industry leaders in the global human microbiome market that are included in our report are Seres Therapeutics, Inc., Evelo Biosciences, Inc., Synlogic, SECOND GENOME, Synthetic Biologics, Inc., YSOPIA Bioscience, 4D pharma plc, DuPont de Nemours, Inc., BiomX Inc., Sun Genomics, Inc., Viome Life Sciences, Inc., and others.

Table of Contents

1. Market Definition2. Assumptions & Acronyms3. Research Methodology4. Executive Summary5. Market Dynamics6. Value Chain Analysis7. Regulatory & Standards Landscape8. Industry Risk Analysis9. Impact of COVID-19 on the Human Microbiome Market10. Analysis of Upcoming Human Microbiome Projects
11. Analysis of Therapeutic Products
11.1. Product Type
11.2. Pros
11.3. Cons
12. Pipeline Analysis13. Analysis on Skin Microbiome-Focused Products14. Product Feature Analysis
15. Competitive Landscape
15.1. Market Share Analysis, 2021
15.2. Seres Therapeutics, Inc.
15.2.1. Detailed Overview
15.2.2. Assessment of Key Offering
15.2.3. Predictive Strategies & Positioning vs. Current Positioning
15.2.4. Analysis on Growth Strategies
15.2.5. Exhaustive Analysis on Key Financial Indicators
15.2.6. Recent Developments
15.3. Evelo Biosciences, Inc.
15.4. Synlogic
15.5. SECOND GENOME
15.6. Synthetic Biologics, Inc.
15.7. YSOPIA Bioscience
15.8. 4D pharma plc
15.9. DuPont de Nemours, Inc.
15.10. BiomX Inc.
15.11. Sun Genomics, Inc.
15.12. Viome Life Sciences, Inc.
16. Global Human Microbiome Market
16.1. Market Overview
16.2. By Value (USD Million)
16.3. Market Segmentation
16.3.1. By Product
16.3.1.1. Probiotics
16.3.1.2. Prebiotics
16.3.1.3. Diagnostic Tests
16.3.1.4. Drugs
16.3.1.5. Others
16.3.2. By Disease Type
16.3.2.1. Infectious Disease
16.3.2.2. Obesity
16.3.2.3. Diabetes
16.3.2.4. Gastrointestinal Diseases
16.3.2.5. Cancer
16.3.2.6. Cardiovascular Diseases
16.3.2.7. Others
16.3.3. By Organism Type
16.3.3.1. Aerobic Organisms
16.3.3.2. Obligate & Facultative Anaerobes
16.3.3.3. Genetically Engineered Strains
16.3.3.4. BSL-2 & Spore-Forming Species
16.3.3.5. Others
16.3.4. By Application
16.3.4.1. Therapeutics
16.3.4.1.1. Single Strains or Multi-Strain Consortia
16.3.4.1.2. Liquid or Dried Bulk Drug Susbtance
16.3.4.1.3. Solid Oral Dose
16.3.4.1.4. Other Drug Product Finished Dosage Forms
16.3.4.2. Diagnostics
16.3.5. By Technology
16.3.5.1. Genomics
16.3.5.1.1. Sequencing
16.3.5.1.1.1. Whole Genome Sequencing
16.3.5.1.1.2. 16s rRNA Sequencing Method
16.3.5.1.1.3. Shotgun Metagenomics Sequencing
16.3.5.1.1.4. Others
16.3.5.1.2. Polymerase Chain Reaction
16.3.5.1.3. Other Genomic Techniques
16.3.5.2. Proteomics
16.3.5.3. Metabolomics
16.3.6. By Region
16.3.6.1. North America
16.3.6.2. Europe
16.3.6.3. Asia Pacific
16.3.6.4. Latin America
16.3.6.5. Middle East & Africa
17. North America Human Microbiome Market
17.1. Market Overview
17.2. By Value (USD Million)
17.3. Market Segmentation
17.3.1. By Product
17.3.1.1. Probiotics
17.3.1.2. Prebiotics
17.3.1.3. Diagnostic Tests
17.3.1.4. Drugs
17.3.1.5. Others
17.3.2. By Disease Type
17.3.2.1. Infectious Disease
17.3.2.2. Obesity
17.3.2.3. Diabetes
17.3.2.4. Gastrointestinal Diseases
17.3.2.5. Cancer
17.3.2.6. Cardiovascular Diseases
17.3.2.7. Others
17.3.3. By Organism Type
17.3.3.1. Aerobic Organisms
17.3.3.2. Obligate & Facultative Anaerobes
17.3.3.3. Genetically Engineered Strains
17.3.3.4. BSL-2 & Spore-Forming Species
17.3.3.5. Others
17.3.4. By Application
17.3.4.1. Therapeutics
17.3.4.1.1. Single Strains or Multi-Strain Consortia
17.3.4.1.2. Liquid or Dried Bulk Drug Susbtance
17.3.4.1.3. Solid Oral Dose
17.3.4.1.4. Other Drug Product Finished Dosage Forms
17.3.4.2. Diagnostics
17.3.5. By Technology
17.3.5.1. Genomics
17.3.5.1.1. Sequencing
17.3.5.1.1.1. Whole Genome Sequencing
17.3.5.1.1.2. 16s rRNA Sequencing Method
17.3.5.1.1.3. Shotgun Metagenomics Sequencing
17.3.5.1.1.4. Others
17.3.5.1.2. Polymerase Chain Reaction
17.3.5.1.3. Other Genomic Techniques
17.3.5.2. Proteomics
17.3.5.3. Metabolomics
17.3.6. By Country
17.3.6.1. United States
17.3.6.2. Canada
18. Europe Human Microbiome Market
18.1. Market Overview
18.2. By Value (USD Million)
18.3. Market Segmentation
18.3.1. By Product
18.3.2. By Disease Type
18.3.3. By Organism Type
18.3.4. By Application
18.3.5. By Technology
18.3.6. By Country
18.3.6.1. Germany
18.3.6.2. United Kingdom
18.3.6.3. France
18.3.6.4. Italy
18.3.6.5. Spain
18.3.6.6. Russia
18.3.6.7. Rest of Europe
19. Asia Pacific Human Microbiome Market
19.1. Market Overview
19.2. By Value (USD Million)
19.3. Market Segmentation
19.3.1. By Product
19.3.2. By Disease Type
19.3.3. By Organism Type
19.3.4. By Application
19.3.5. By Technology
19.3.6. By Country
19.3.6.1. China
19.3.6.2. Japan
19.3.6.3. South Korea
19.3.6.4. Australia
19.3.6.5. India
19.3.6.6. Singapore
19.3.6.7. Rest of APAC
20. Latin America Human Microbiome Market
20.1. Market Overview
20.2. By Value (USD Million)
20.3. Market Segmentation
20.3.1. By Product
20.3.2. By Disease Type
20.3.3. By Organism Type
20.3.4. By Application
20.3.5. By Technology
20.3.6. By Country
20.3.6.1. Brazil
20.3.6.2. Argentina
20.3.6.3. Mexico
20.3.6.4. Rest of Latin America
21. Middle East & Africa Human Microbiome Market
21.1. Market Overview
21.2. By Value (USD Million)
21.3. Market Segmentation
21.3.1. By Product
21.3.2. By Disease Type
21.3.3. By Organism Type
21.3.4. By Application
21.3.5. By Technology
21.3.6. By Country
21.3.6.1. GCC
21.3.6.2. Israel
21.3.6.3. South Africa
21.3.6.4. Rest of Middle East & Africa

Companies Mentioned

  • Seres Therapeutics Inc.
  • Evelo Biosciences Inc.
  • Synlogic
  • SECOND GENOME
  • Synthetic Biologics Inc.
  • YSOPIA Bioscience
  • 4D pharma plc
  • DuPont de Nemours Inc.
  • BiomX Inc.
  • Sun Genomics Inc.
  • Viome Life Sciences Inc.

Related Topics

Related Reports

Global Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics), Application (Therapeutic, Diagnostics), Disease (Cancer, Gastrointestinal, Infectious), Type (Peptide, Live Biotherapeutic Product, FMT), and Region - Forecast to 2029 - Product Image

Global Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics), Application (Therapeutic, Diagnostics), Disease (Cancer, Gastrointestinal, Infectious), Type (Peptide, Live Biotherapeutic Product, FMT), and Region - Forecast to 2029

  • Report
  • 183 Pages
  • Global
From
Global Human Microbiome Market by Disease (Acute Diarrhea, Autoimmune Disorders, Cancer), Technology (16s rRNA Sequencing, Cell Culture Technology, Computational Tools), Product, Therapeutic Area, Application - Forecast 2023-2030 - Product Image

Global Human Microbiome Market by Disease (Acute Diarrhea, Autoimmune Disorders, Cancer), Technology (16s rRNA Sequencing, Cell Culture Technology, Computational Tools), Product, Therapeutic Area, Application - Forecast 2023-2030

  • Report
  • 183 Pages
  • Global
From
Global Human Microbiome Therapeutics Market 2023-2027 - Product Image

Global Human Microbiome Therapeutics Market 2023-2027

  • Report
  • 159 Pages
  • Global
From
Global Human Microbiome Market Report and Forecast 2023-2031 - Product Image

Global Human Microbiome Market Report and Forecast 2023-2031

  • Report
  • 140 Pages
  • Global
From
Microbiome Sequencing Services - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Microbiome Sequencing Services - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 120 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.